Literature DB >> 35322413

Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020.

Citadel J Cabasag1, Paula J Fagan1,2, Jacques Ferlay1, Jerome Vignat1, Mathieu Laversanne1, Lihua Liu3,4, Maaike A van der Aa5, Freddie Bray1, Isabelle Soerjomataram1.   

Abstract

Ovarian cancer remains to have relatively poor prognosis particularly in low-resourced settings. It is therefore important to continually examine the burden of ovarian cancer to identify areas of disparities. Our study aims to provide an overview of the global burden of ovarian cancer using the GLOBOCAN 2020 estimates by country, world region, and Human Development Index (HDI) levels, as well as the predicted future burden by the year 2040 by HDI. Age-standardized incidence and mortality rates for ovarian cancer in 185 countries were calculated by country, world region, and for the four-tier HDI. The number of new cases and deaths were projected for the year 2040 based on demographic projections by HDI category. Approximately 314 000 new ovarian cancer cases and 207 000 deaths occurred in 2020. There were marked geographic variations in incidence rates, with the highest rates observed in European countries with very high HDI and low rates were found in African countries within the lowest HDI group. Comparable mortality rates were observed across the four-tier HDI. Relative to 2020 estimates, our projection for 2040 indicates approximately 96% and 100% increase in new ovarian cancer cases and deaths, respectively, among low HDI countries compared to 19% and 28% in very high HDI countries. Our study highlights the disproportionate current and future burden of ovarian cancer in countries with lower HDI levels, calling for global action to reduce the burden and inequality of ovarian cancer in access to quality cancer care and treatment.
© 2022 The World Health Organization. The World Health Organization retains copyright and all other rights in the manuscript of this article as submitted for publication.

Entities:  

Keywords:  cancer disparities; incidence; mortality; ovarian cancer

Mesh:

Year:  2022        PMID: 35322413     DOI: 10.1002/ijc.34002

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  3 in total

1.  Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism.

Authors:  Shree Bose; Haipei Yao; Qiang Huang; Regina Whitaker; Christopher D Kontos; Rebecca A Previs; Xiling Shen
Journal:  J Ovarian Res       Date:  2022-10-20       Impact factor: 5.506

2.  HBOC syndrome with an uncharacterized variant in the BRCA1 gene in a patient diagnosed with endometrial cancer after surgery for bilateral breast cancer: A case report.

Authors:  Yasushi Mabuchi; Yuta Hamano; Sawako Minami; Nami Ota; Kazuhiko Ino
Journal:  Oncol Lett       Date:  2022-07-27       Impact factor: 3.111

Review 3.  Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Rodrigo Vicente; Diogo Alpuim Costa; Marina Vitorino; Ana Duarte Mendes; Catarina Santos; Mário Fontes-Sousa
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.